{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.1","upperLimit":"5","value":"1.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"}],"units":"Participants"}],"description":"Time to progresion is the defined as the time from study entry to disease progression (PD) or death. Patients without PD are censored at the date of last disease evaluation. PD is defined as a greater than 25% increase in serum monoclonal IgM electrophoresis confirmed by a second measurement at least 2 weeks apart, or progression of clinically significant findings due to disease or symptoms attributable to WM.","dispersionType":"95% Confidence Interval","groups":[{"description":"bortezomib and rituximab\n\nBortezomib: Once weekly for 3 weeks\n\nRituximab: Intravenously once a week for the first and fourth weeks of a cycle","id":"OG000","title":"Bortezomib and Rituximab"}],"paramType":"MEDIAN","populationDescription":"All enrolled participants.","reportingStatus":"POSTED","timeFrame":"5 Years","title":"Time to Progression in Patients With WM","type":"SECONDARY","unitOfMeasure":"years"}